[go: up one dir, main page]

DE69636052D1 - Mpl-liganden analoga - Google Patents

Mpl-liganden analoga

Info

Publication number
DE69636052D1
DE69636052D1 DE69636052T DE69636052T DE69636052D1 DE 69636052 D1 DE69636052 D1 DE 69636052D1 DE 69636052 T DE69636052 T DE 69636052T DE 69636052 T DE69636052 T DE 69636052T DE 69636052 D1 DE69636052 D1 DE 69636052D1
Authority
DE
Germany
Prior art keywords
mpl
mpl ligand
analogs
ligand analogue
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636052T
Other languages
English (en)
Other versions
DE69636052T2 (de
Inventor
Steven G Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/388,779 external-priority patent/US5696250A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE69636052D1 publication Critical patent/DE69636052D1/de
Publication of DE69636052T2 publication Critical patent/DE69636052T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DE69636052T 1995-02-15 1996-02-13 Mpl-liganden analoga Expired - Fee Related DE69636052T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US388779 1995-02-15
US08/388,779 US5696250A (en) 1995-02-15 1995-02-15 DNA encoding megakaryocyte growth and development factor analogs
US591070 1996-02-09
US08/591,070 US5756083A (en) 1995-02-15 1996-02-09 Mpl ligand analogs
PCT/US1996/002492 WO1996025498A2 (en) 1995-02-15 1996-02-13 Mpl ligand analogs

Publications (2)

Publication Number Publication Date
DE69636052D1 true DE69636052D1 (de) 2006-05-24
DE69636052T2 DE69636052T2 (de) 2007-04-12

Family

ID=27012437

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636052T Expired - Fee Related DE69636052T2 (de) 1995-02-15 1996-02-13 Mpl-liganden analoga

Country Status (10)

Country Link
EP (1) EP0811064B1 (de)
JP (1) JP3836877B2 (de)
CN (1) CN1161468C (de)
AT (1) ATE323724T1 (de)
AU (1) AU691410B2 (de)
CA (1) CA2209298C (de)
DE (1) DE69636052T2 (de)
MX (1) MX9705943A (de)
NZ (1) NZ303588A (de)
WO (1) WO1996025498A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US8192955B1 (en) 1994-01-03 2012-06-05 Genentech, Inc. Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
US8241900B1 (en) 1994-01-03 2012-08-14 Genentech, Inc. mpl ligand
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
CA2265464C (en) * 1996-09-13 2007-06-26 Transkaryotic Therapies, Inc. Therapy for .alpha.-galactosidase a deficiency
AU4344697A (en) * 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
KR20000006549A (ko) * 1998-06-30 2000-01-25 윤재승 생체내혈소판증식효능이향상된신규한트롬보포이에틴유도체
US6376242B1 (en) 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
EP1670821A4 (de) * 2003-10-09 2006-11-29 Daewoong Co Ltd Verfahren zur aufreinigung von humanem thrombopoietin mit hohem sialsäuregehalt
KR101040396B1 (ko) 2009-01-20 2011-06-09 한올바이오파마주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
WO2013130604A1 (en) * 2012-02-27 2013-09-06 Biogen Idec Ma Inc. High-throughput method for sialic acid quantitation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19500030A1 (de) * 1994-01-03 1995-07-06 Genentech Inc Thrombopoietin
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
BR9506017A (pt) * 1994-03-31 1997-10-14 Amagen Inc Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um polipeptideo Mgdf e poipeptideo glicol solúvel em água a um polipeptideo mgdf
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
CA2212006A1 (en) * 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands

Also Published As

Publication number Publication date
EP0811064B1 (de) 2006-04-19
EP0811064A2 (de) 1997-12-10
NZ303588A (en) 1999-02-25
HK1009151A1 (en) 1999-09-10
CN1182453A (zh) 1998-05-20
CN1161468C (zh) 2004-08-11
HK1005807A1 (en) 1999-01-29
JP3836877B2 (ja) 2006-10-25
JPH11500904A (ja) 1999-01-26
DE69636052T2 (de) 2007-04-12
AU4994696A (en) 1996-09-04
WO1996025498A3 (en) 1997-03-20
CA2209298C (en) 2001-12-18
AU691410B2 (en) 1998-05-14
MX9705943A (es) 1997-10-31
ATE323724T1 (de) 2006-05-15
WO1996025498A2 (en) 1996-08-22
CA2209298A1 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
CA2147124A1 (en) Erythropoietin analogs
EP1440980A3 (de) Peptidanaloge des menschlichen, basischen Myelinproteins
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE114169T1 (de) Morphogenetisches knochenprotein.
DE69636052D1 (de) Mpl-liganden analoga
ATE226634T1 (de) Fibronektin bindendes protein
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
HU9200548D0 (en) Improved activity process of recombined proteins
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
ATE363488T1 (de) Zusammensetzungen von stammzellfaktor (scf)- analogen und auf diese bezogene verfahren
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee